title: Botulinum toxin type A on oral health in treating sialorrhea in children with cerebral palsy: a randomized, double-blind, placebo-controlled study.
abstract: Intrasalivary gland injection of botulinum toxin type A is known to treat sialorrhea effectively in children with cerebral palsy. However, oral health may be compromised with escalating dose. In this randomized, double-blind, and placebo-controlled pilot trial, the authors aim to determine the therapeutic effect of low-dose, ultrasonography-controlled botulinum toxin type A injection to bilateral parotid and submandibular glands on oral health in the management of sialorrhea. Twenty children diagnosed with cerebral palsy were randomly assigned to 2 groups. The treatment group received botulinum toxin type A injections, whereas the control received normal saline in the same locations. The authors evaluated subjective drooling scales, salivary flow rate, and oral health (salivary compositions and cariogenic bacterial counts). A significant decrease was found in salivary flow rate at the 1- and 3-month follow-up in the botulinum toxin-treated group. The authors suggest that current protocol can effectively manage sialorrhea while maintaining oral health.
authors.affiliation: Department of Physical Medicine and Rehabilitation, Chang Gung Memorial Hospital, Taoyuan, Taiwan.
authors.forename: Katie Pei-Hsuan
authors.initials: KP
authors.lastname: Wu
authors.forename: Jyh-Yuh
authors.initials: JY
authors.lastname: Ke
authors.forename: Chung-Yao
authors.initials: CY
authors.lastname: Chen
authors.forename: Chia-Ling
authors.initials: CL
authors.lastname: Chen
authors.forename: Ming-Yen
authors.initials: MY
authors.lastname: Chou
authors.forename: Yu-Cheng
authors.initials: YC
authors.lastname: Pei
mesh_terms: D000293:Adolescent; D019274:Botulinum Toxins, Type A / Q000008:administration & dosage* / Q000009:adverse effects; D002547:Cerebral Palsy / Q000150:complications*; D002648:Child; D002675:Child, Preschool; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D009498:Neurotoxins / Q000008:administration & dosage / Q000009:adverse effects; D010865:Pilot Projects; D010919:Placebos; D012463:Saliva / Q000737:chemistry / Q000187:drug effects* / Q000378:metabolism*; D012798:Sialorrhea / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology*
chemical_list: D009498:Neurotoxins; D010919:Placebos; D019274:Botulinum Toxins, Type A